Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Feb 8:38:137.
doi: 10.11604/pamj.2021.38.137.20560. eCollection 2021.

Treatment of chronic hepatitis C with sofosbuvir in a hemodialysis patient: a case report

Marius Djoumbissie Tchoupe  1 , Hanen Chaker  1 , Mona Boudabbous  2 , Salma Toumi  1 , François Pegdebamba Kissou  1 , Saba Gargouri  3 , Khawla Kammoun  1 , Faiçal Jarraya  1 , Nabil Tahri  2 , Soumaya Yaich  1 , Mohamed Ben Hmida  1
Affiliations
Case Reports

Treatment of chronic hepatitis C with sofosbuvir in a hemodialysis patient: a case report

Marius Djoumbissie Tchoupe et al. Pan Afr Med J. .

Abstract

The treatment of chronic hepatitis C virus (HCV) infection in chronic hemodialysis patients remains an issue of great concern for nephrologists. In 2008 the kidney disease improving global outcomes working group suggested the use of pegylated interferon in end stage kidney disease patients treated by dialysis. Since then, series and some clinical trials on different direct-acting antiviral agents have shown better efficacy and tolerance than interferon-based regimens. Data on the efficacy, tolerance and the right dose of sofosbuvir in this population are still unclear. We report a case of chronic HCV genotype 1b infection in a 47-year-old patient on maintenance hemodialysis successfully treated by a combination of sofosbuvir and ledipasvir for 12 weeks. Evolution was marked by the complete regression of the hepatic cytolysis, a complete and sustained virologic response with HCV viral load undetectable for a 24 months follow-up period. No adverse reaction was found. The treatment of HCV genotype 1 or 4 infection in patients on maintenance hemodialysis is possible with sofosbuvir based regimens with a good efficacy/safety ratio in the absence of current recommended drugs for patients with eGFR<30ml/min/1.73m2. The prescription of sofosbuvir should be encouraged amongst this population in this setting.

Keywords: Hemodialysis; case report; hepatitis C; sofosbuvir; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

References

    1. Kidney disease: improving global outcomes (KDIGO) Kidney Int Suppl. 109. 2008. Apr, KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation and treatment of hepatitis C in chronic kidney disease; pp. S1–99. - PubMed
    1. Fabrizi F, Takkouche B, Lunghi G, Dixit V, Messa P, Martin P. The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies. J Viral Hepat. 2007 Oct;14(10):697–703. - PubMed
    1. Jadoul M, Martin P. Hepatitis C treatment in chronic kidney disease patients: the kidney disease improving global outcomes perspective. Blood Purif. 2017;43(1-3):206–209. - PubMed
    1. Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group. KDIGO 2018 clinical practice guideline for the prevention, diagnosis, evaluation and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl (2011) 2018 Oct;8(3):91–165. - PMC - PubMed
    1. Gane EJ, Robson RA, Bonacini M, Maliakkal B, Liu L, Sajwani K, et al. Safety, anti-viral efficacy and pharmacokinetics (PK) of sofosbuvir (SOF) in patients with severe renal impairment. Hepatology. 2014;60:667A-A.

Publication types

MeSH terms